Wednesday, December 13, 2006

CETP inhibitors don't seem to be all bad

Merck's CETP inhibitor MK-859, which is in the same family as torcetrapib which Pfizer discontinued after an excess of cardiovascular problems and deaths, does not seem to cause heart attacks and strokes. So, apparently torcetrapib had some other mechanism than CETP inhibition which caused the problems, or perhaps Merck's version has some other cardioprotective side effect.

(via Pharmagossip)